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Abstract Objective: To determine
the influence of using different de-
nominators on risk estimates of ven-
tilator-associated pneumonia (VAP).
Design and setting: Prospective co-
hort study in the medical ICU of a
large teaching hospital. Patients: All
consecutive patients admitted for
more than 48 h between October
1995 and November 1997. Measure-
ments and results: We recorded all
ICU-acquired infections using modi-
fied CDC criteria. VAP rates were
reported per 1,000 patient-days, pa-
tient-days at risk, ventilator-days,
and ventilator-days at risk. Of the
1,068 patients admitted, VAP devel-
oped in 106 (23.5%) of those me-
chanically ventilated. The incidence
of the first episode of VAP was 22.8
per 1,000 patient-days (95% CI
18.7–27.6), 29.6 per 1,000 patient-
days at risk (24.2–35.8), 35.7 per
1,000 ventilator-days (29.2–43.2),
and 44.0 per 1,000 ventilator-days at
risk (36.0–53.2). When considering
all episodes of VAP (n=127), infec-
tion rates were 27.3 episodes per
1,000 ICU patient-days (95% CI
22.6–32.1) and 42.8 episodes per
1,000 ventilator-days (35.3–50.2).
Conclusions: The method of report-
ing VAP rates has a significant im-
pact on risk estimates. Accordingly,
clinicians and hospital management
in charge of patient-care policies
should be aware of how to read and
compare nosocomial infection rates.
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Nosocomial pneumonia is the leading infection in criti-
cal care and significantly impacts on patient mortality
and morbidity [1, 2]. The proportion of patients who ac-
quire the infection ranges from 10% to 65% [3, 4]. Venti-
lator-associated pneumonia (VAP) occurs in approx.
8–28% of mechanically ventilated patients, with a re-
ported incidence of 1–3% per day of mechanical ventila-
tion [4, 5, 6]. A comparison of rates is difficult due not
only to differences in diagnostic procedures, definitions
used, and population case-mix but also to the frequent
lack of appropriate denominators [5, 6, 7]. To facilitate
and foster benchmarking between units and hospitals, the
National Nosocomial Infection Surveillance (NNIS)
system of the Centers for Disease Control and Preven-
tion (CDC) recommends expressing VAP as the number
of infectious episodes per 1,000 ventilator-days. In its
latest data report covering the period from January 1995
to June 2001 VAP ranged from 4.9 (25th–75th percen-
tiles 1.4–7.7), 7.3 (3.8–9.0), and 8.4 (4.1–11.4) to 13.2
(7.7–14.9) episodes per 1,000 ventilator-days in pediat-
P. Eggimann · S. Hugonnet · H. Sax
S. Touveneau · D. Pittet (✉)
Infection Control Program, 
Department of Internal Medicine,
University Hospitals of Geneva,




P. Eggimann · J.-C. Chevrolet
Medical Intensive Care Unit,
Department of Internal Medicine,
University Hospitals of Geneva,
1211 Geneva 14, Switzerland
2087
ric, medical, coronary, and surgical ICUs, respectively
[8].
The present study describes the epidemiology of VAP
in a medical ICU, underscores the effect of the use of
different denominators on risk estimates, and highlights
some poorly recognized caveats of risk and rate compari-
son [9].
Materials and methods
The University of Geneva Hospitals are a 2300-bed tertiary care
center admitting approx. 40,000 patients annually. An average of
1400 patients are admitted each year to the 18-bed medical ICU,
for a mean length of stay of 4 days. During the study period 1,049
patients were surveyed for 1,068 distinct ICU stays. Median age
was 63 years (range 16–92); 622 patients (58%) were male. Medi-
an ICU stay was 5 days (range 2–134). Main admission diagnoses
concerned infectious (39%), cardiovascular (24%), and pulmonary
(18%) conditions. Overall 452 patients (42%) benefited from 
mechanical ventilation for a median duration of 3 days (range
1–123); 27% were mechanically ventilated for 1 day.
Prospective, on-site surveillance was conducted by an infec-
tion control nurse who was also fully trained in intensive care
medicine. She visited the ICU daily (5/7) and extracted data from
medical records, kardex, interviews with nurses and physicians,
microbiology, and radiographic reports. All surveillance records
were validated by two infection control physicians and one inten-
sive care specialist [10]. All patients admitted for more than 48 h
between October 1995 and November 1997 were prospectively
followed during their entire ICU stay and 5 days after discharge.
Definitions
All nosocomial infections were defined according to modified 
criteria of the CDC [10, 11]. In particular, VAP was defined ac-
cording to the criteria of the American College of Chest Physi-
cians-American Thoracic Society consensus conferences [12]. The
diagnosis of VAP in a patient mechanically ventilated for 48 h or
more with a clinical suspicion of pneumonia required two of the
following criteria: fever (increase of >1°C or body temperature
>38.3°C), leukocytosis (25% increase and a value >10,000 mm3)
or leukopenia (25% decrease and a value <5,000 mm3); and puru-
lent tracheal secretions (>25 neutrophils per high-power field);
and one of the following: (a) new or persistent infiltrates on chest
radiographs; (b) same micro-organism isolated from pleural fluid
and tracheal secretions or radiographic cavitation or histopatho-
logical demonstration of pneumonia; (c) positive cultures obtained
from bronchoalveolar lavage (>104 colony forming units/ml).
Statistical analysis
The incidence of VAP was expressed as the number of episodes
per 1,000 patient-days and per 1,000 patient-days at risk, or epi-
sodes per 1,000 ventilator-days and per 1,000 ventilator-days at
risk, with 95% confidence intervals (95% CI) based on the 
Poisson distribution. Days at risk or ventilator-days at risk were
defined as the number of days or ventilator-days before the onset
of first infection. All analyses were performed using the Stata soft-
ware package 6.0 (Stata, College Station, Tex., USA).
Results
ICU and hospital mortality were 16.8% and 24%, respec-
tively. A total of 554 nosocomial infections developed in
281 patients (26.3%). Rates of infection and infected pa-
tients were 70.7 and 35.8 per 1,000 patient-days, respec-
tively. Leading sites of infection were lower respiratory
tract (28.7%), bloodstream (20.4%), exit-site catheter
(13.5%), and the urinary tract (11.2%). We recorded 159
episodes of pneumonia occurring in 138 patients that
were ICU acquired. Of these, 127 were VAP, including
106 first episodes of VAP. When considering all episodes
of VAP, infection rates were 27.3 episodes per 1,000 ICU
patient-days (95% CI 22.6–32.1) and 42.8 episodes per
1,000 ventilator-days (95% CI 35.3–50.2). Rates of first
episode of VAP expressed according to the different de-
nominators are shown in Table 1. Thirty-three episodes
developed within 4 days of intubation and were consid-
ered as early onset VAP.
Discussion
Successful infection control strategies are based on sur-
veillance and feedback of infection rates [7, 13, 14].
Based on the results of the SENIC study in the 1970s,
healthcare-associated infection rates decreased by an av-
erage of 32% in hospitals where infection control pro-
grams were implemented, and increased by 18% in other
institutions over a 5-year period [13]. Accordingly, such
programs were rapidly imposed in the United States as
an important criterion for hospital accreditation [15]. Da-
ta generated by surveillance may be used for resources
allocation, quality of care assessment, and benchmarking
[7, 8, 16].
Determinants of VAP rates include the surveillance
strategy employed, case mix, case definition, diagnostic
procedures, and the way in which rates are expressed.
All of these may alter infection rates and jeopardize
benchmarking. The choice of the most appropriate de-
Table 1 Incidence of ventila-
tor-associated pneumonia ac-
cording to different denomina-
tors; medical ICU 1995–1997,
University of Geneva Hospitals
Total of days Median (range) Infection rates per 
1,000 (95% CI)a
ICU days 4,651 7 (2–134) 22.8 (18.7–27.6)
ICU days at risk 3,579 6 (2–67) 29.6 (24.2–35.8)
Ventilator-days 2,969 3 (1–123) 35.7 (29.2–43.2)
Ventilator-days at risk 2,408 3 (1–53) 44.0 (36.0–53.2)a Only the first episode of VAP
is considered (n=106)
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nominator is often not straightforward, and it is self-evi-
dent that rates will vary accordingly. However, this has
never been explored in the field of nosocomial infection,
particularly for VAP. We focus in this study on the influ-
ence of the denominator.
Diagnosis of VAP remains a controversial issue [6,
17]. We used surveillance-based criteria [11, 12, 18]
which do not rely exclusively on the microbiological re-
sults obtained by invasive sampling techniques [6, 19].
Such an approach might be associated with misclassifi-
cation bias but is more suitable for clinical practice or
surveillance purposes and is currently used in most cen-
ters actively promoting infection control [16, 19]. Impor-
tantly, although the use of a different diagnostic strategy
could have resulted in different infection rates, it would
not, however, have changed the current findings regard-
ing the impact of the use of different denominators on
risk estimates.
We focused in this study on the first episode of VAP
for two main reasons. First, there is still considerable de-
bate on the definition of VAP, and the difficulty of diag-
nosing a second episode is enhanced, thus increasing
misclassification of the second episode. Second, if con-
sidering all episodes, the concepts of “days at risk” and
“ventilator-days at risk” are impossible to assess. Indeed,
one should know when the first episode resolves, and
when the patient is again at risk for a second episode.
Most studies report VAP rates per patient-days [7],
which does not take into account the main risk factor for
infection, i.e., exposure to mechanical ventilation, thus
leading to an important underestimation of the incidence
of infection. Patient case-mix and ICU transfer policy
may further bias the estimate and jeopardize benchmark-
ing [3]. If infection rates are expressed per patient-days,
a prolonged ICU stay underestimates the VAP rate,
whereas an ICU with a high proportion of patients with a
short length of stay is penalized by reporting a higher
rate. Because the daily conditional risk of acquiring VAP
peaks at around day 5 [4], a similar bias occurs when
rates are expressed per ventilator-days: the longer the du-
ration of mechanical ventilation, the lower is the rate.
Considering only ventilator-days at risk, and therefore
excluding ventilator-days after the onset of VAP, yields a
more appropriate risk estimate and makes benchmarking
feasible after case-mix adjustment [9, 20]. Because the
daily conditional risk of acquiring VAP is not constant
over time [4], ventilator-days may not be the best de-
nominator to express VAP rates. Instead, stratified or
standardized rates might be technically more suitable,
but benchmarking is based so far on rates computed on
ventilator-days. Moreover, elements such as appropriate
surveillance strategies, case definition, and denominators
have a greater impact on infection rates than adjustment
for varying daily conditional risk.
We show that the incidence of infection expressed as
episodes per 1,000 patient-days underestimates that ex-
pressed as episodes per 1,000 ventilator-days by about
40%. In addition, considering days at risk or ventilator-
days at risk additionally underestimates rates by about
20%. These differences may be of paramount importance
while comparison of nosocomial infection rates, includ-
ing VAP, does actually support benchmarking between
units and hospitals [8, 13, 16] and has been recently in-
corporated into the process of quality management in
many institutions [21].
Risk adjustment to publicly compare outcomes across
healthcare providers constitutes one of the major chal-
lenges of today’s highly charged, competitive medical
environment.
Conclusions
We raise a flag of concern not only for the comparison of
infection rates among hospitals but also for the “the risks
of risk assessment” as raised by Iezzoni [9]. According-
ly, clinicians and hospital management in charge of pa-
tient-care policies should be aware of how to read and
compare nosocomial infection rates and to become 
familiar with the underlying concepts of infection con-
trol and its potential role for prevention. Failure to rec-
ognize these issues will lead to biased comparisons and
compromise meaningful benchmarking between health-
care institutions.
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